Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | -8,102.6% |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $3 |
| Operating Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | -524,298.4% |
| Other Income/Exp. Net | -$0 | $1 | $1 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$1 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | $6 | -$1 | -$3 |
| % Margin | – | – | – | -570,922.8% |
| EPS | -0.023 | 0.12 | -0.045 | -0.11 |
| % Growth | -118.9% | 365.5% | 58.9% | – |
| EPS Diluted | -0.023 | 0.12 | -0.045 | -0.11 |
| Weighted Avg Shares Out | 99 | 48 | 33 | 32 |
| Weighted Avg Shares Out Dil | 99 | 48 | 33 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$1 | -$3 |
| % Margin | – | – | – | -524,539.7% |